Age >= 6 years at the NCI clinical center (>= 18 years at other participating sites)Xx_NEWLINE_xXPatient is at least 18 years of ageXx_NEWLINE_xXBe ?18 years of age.Xx_NEWLINE_xXAge ? 18 years at time of informed consentXx_NEWLINE_xXParts A & C: patients must be >= 12 months and < 18 years of age at the time of study enrollmentXx_NEWLINE_xXPart B7: patients must be >= 12 months and < 18 years of age at the time of study enrollmentXx_NEWLINE_xXCreatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:\r\n* Age 1 to < 2 years: maximum serum creatinine (mg/dL) 0.6 for males and females\r\n* Age 2 to < 6 years: 0.8 for males and females\r\n* Age 6 to < 10 years: 1 for males and females\r\n* Age 10 to < 13 years: 1.2 for males and females\r\n* Age 13 to < 16 years: 1.5 for males and 1.4 for females\r\n* Age >= 16 years: 1.7 for males and 1.4 for femalesXx_NEWLINE_xXAge 50.0-75.0 years.Xx_NEWLINE_xXMust be ? 18 years of age.Xx_NEWLINE_xXAge ? 10 yearsXx_NEWLINE_xXSubject is between 18 years old and 75 years old, inclusiveXx_NEWLINE_xXAge of 18 years or older; in addition, patients age 12 to 17 years may enroll beginning in Cohort 2 if weight ? 40 kgXx_NEWLINE_xXPatients with body mass index (BMI) < 3rd percentile for age, as defined by WHO criteria for patients 1-2 years of age and Centers for Disease Control and Prevention (CDC) criteria for patients > 2 years of age, are not eligibleXx_NEWLINE_xXParticipants must be skeletally mature defined as females with a bone age >= 15 years and males with a bone age >= 17 yearsXx_NEWLINE_xX40 years of age or older at time of DCIS diagnosisXx_NEWLINE_xXEfficacy Phase: Patients must be =< 40 years of age at the time of enrollmentXx_NEWLINE_xXPatients must be >= 18 years of ageXx_NEWLINE_xXAge >= 14 years (>= 18 years in Germany)Xx_NEWLINE_xXAge ?18 years (or per national guidelines).Xx_NEWLINE_xXAge 18 years or aboveXx_NEWLINE_xXAdult patients ? 18 yearsXx_NEWLINE_xXAge of 18 years or olderXx_NEWLINE_xXSubjects must be age ? 21 years at initial diagnosisXx_NEWLINE_xXMales or females age greater than or equal to 18 years at the time of informed consentXx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXSubject is at least 18 years of age.Xx_NEWLINE_xXAge >= 18 years.Xx_NEWLINE_xXSubjects must be age ? 21 years at initial diagnosisXx_NEWLINE_xXAdult (? 18 years old)Xx_NEWLINE_xXMust be 18 years or olderXx_NEWLINE_xXMen and women ?18 years of ageXx_NEWLINE_xXMales or females who are 18 years or olderXx_NEWLINE_xXAdults (Age ? 18 years)Xx_NEWLINE_xXSubjects must be ?18 years of age.Xx_NEWLINE_xXMale or females with an age ? 18 years.Xx_NEWLINE_xXAge ? 18Xx_NEWLINE_xXAge ? 18 years of ageXx_NEWLINE_xXBe > 18 years of age on day of signing informed consentXx_NEWLINE_xXAge >/=18 years at the time the ICF is signedXx_NEWLINE_xXMen and women ?18 years.Xx_NEWLINE_xXAged 18 years and older on the day of signing informed consentXx_NEWLINE_xXAge . 18 years old at the time of signing the informed consentXx_NEWLINE_xXAge greater than or equal to (>/=) 18 yearsXx_NEWLINE_xXMales or females, ?18 years of ageXx_NEWLINE_xXAge >/= 18 years;Xx_NEWLINE_xXAge > 18 years.Xx_NEWLINE_xXSubjects ? 18 years of age.Xx_NEWLINE_xXSubjects must be 18 years of age or older at the date of consent.Xx_NEWLINE_xXAge: 18 yearsXx_NEWLINE_xXAged 18 years or older.Xx_NEWLINE_xXPatients must be ?18 years of ageXx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAt least 18 or older of age on day of signing informed consentXx_NEWLINE_xXAge ?18 (or age ? 20 of age as required by local regulation).Xx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXAdults age 18-80 yearsXx_NEWLINE_xXAge >21 yearsXx_NEWLINE_xXAge > or = 21 yearsXx_NEWLINE_xXMales or females age ? 18 years at the time of informed consentXx_NEWLINE_xX?18 years of ageXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXMust be age 18 or olderXx_NEWLINE_xXMales and Females at least 18 years of ageXx_NEWLINE_xXBe 18 years of age at the time the informed consent form is signedXx_NEWLINE_xXCOHORT 1: Be >= 18 years of age on day of signing informed consentXx_NEWLINE_xX18 years of age or orderXx_NEWLINE_xXAdults 18 years of age or olderXx_NEWLINE_xXSubject is at least 18 years of age.Xx_NEWLINE_xXAge ? 15 and < 41 yearsXx_NEWLINE_xXBe > 6 months and < 18 years of ageXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXMales or non-pregnant, non-lactating females, ? 18 years of ageXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAdult males or females aged 18 years or overXx_NEWLINE_xXAge greater than or equal to (>/=) 18 yearsXx_NEWLINE_xXPatients age ?18 years at signing the informed consent.Xx_NEWLINE_xXMust be ? 18 years of age at the time of signing the ICF.Xx_NEWLINE_xXPatients ? 18 years oldXx_NEWLINE_xXAge greater than or equal to 18 yearsXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXSubjects ?18 years of age for solid tumor; in the case of midline carcinoma with NUT rearrangement. subjects may be ?16 years of age.Xx_NEWLINE_xXPatients must fit into one of the following categories:\r\n* Age >= 18 years to < 60 years with a cumulative illness rating scale (CIRS) score >= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator\r\n* >= 60 yearsXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXMen and women greater than or equal to 18 years of age.Xx_NEWLINE_xXAge>= 50Xx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xXAge above or equal to 18 yearsXx_NEWLINE_xXMales and females ? 18 years of age at screeningXx_NEWLINE_xXMan or woman >= 18 years old.Xx_NEWLINE_xXPts must be ? 18 years of ageXx_NEWLINE_xXMust be less than 30 years of age at time of original diagnosisXx_NEWLINE_xXPatients must be at least 18 years old.Xx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXAge >18 years.Xx_NEWLINE_xX?18 years of age.Xx_NEWLINE_xXAge > 18 years.Xx_NEWLINE_xXBe ?18 years of age.Xx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xXAmbulatory and ?18 years of age.Xx_NEWLINE_xX?18 years of age.Xx_NEWLINE_xXPatients age ?18 years at signing the informed consent.Xx_NEWLINE_xXAt least 18 years of age at the time of signing the informed consent form.Xx_NEWLINE_xXFemales age ? 18 years oldXx_NEWLINE_xXBe between the ages of ?18 and ?65 yearsXx_NEWLINE_xXSubject is ? 18 years of age at the time of signing the informed consent form (ICF).Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge >18 years and ?75 years.Xx_NEWLINE_xXAge ?60 years; orXx_NEWLINE_xXAbility to give informed consent; all subjects >= 18 years of age must be able to give informed consent; for subjects < 18 years old their legal authorized representative (LAR) (i.e. parent or guardian) must give informed consent; pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those > 7 years of age, when appropriateXx_NEWLINE_xXSt. Jude patients must be between 2 years and =< 21 years of age, on therapy (active patient), or within 3 years of completion of therapy; patients treated at collaborating sites must be =< 24 years oldXx_NEWLINE_xXMale or female participants age ?18 years (or any age ?18 years if that age is considered to be an adult per the local jurisdiction) at the time of informed consentXx_NEWLINE_xX18 years of age and older.Xx_NEWLINE_xX? 18, but < 75 years of ageXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAge >/= 18 yearsXx_NEWLINE_xXINCLUSION - PROCUREMENT: The first six (6) patients treated on the study should be adults (? 18 years [yrs] of age); six adolescents (age 12-18) should be treated before children (? 3 yrs of age) are eligibleXx_NEWLINE_xXINCLUSION - TREATMENT: The first six (6) patients treated on the study should be adults (? 18 yrs of age); six adolescents (age 12-18) should be treated before children (? 3 yrs of age) are eligibleXx_NEWLINE_xX18 years of age at the time of consenting.Xx_NEWLINE_xXAge ?18 years .Xx_NEWLINE_xXMen or women ? 18 years old at the time of signing the ICFXx_NEWLINE_xXPatients ?12 years of ageXx_NEWLINE_xX18 years of age and olderXx_NEWLINE_xXSubjects must be at least 1 and less than or equal to 18 years of age at the time of study entry.Xx_NEWLINE_xXAge >= 21 yearsXx_NEWLINE_xXPatients 18 to 70 years oldXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ? 18.0 years and < 66.0 years at the time of enrollment.Xx_NEWLINE_xXPatients =< 25 years of age will be eligible for the pre-surgical cohort; patients between 18-25 years of age will be treated at the adult Food and Drug Administration (FDA)-approved dose of 960 mg BID and can be enrolled immediately; patients less than 18 years of age will be enrolled and treated at the pediatric MTD once it is defined in the safety cohortXx_NEWLINE_xXPatients =< 25 years of age with evaluable disease will be eligible for the expansion cohort; patients between 18 and 25 years of age will take adult dose of 960 mg BID and are eligible at the initiation of the trial; patients less than 18 years of age will take the MTD once it is defined in the safety cohortXx_NEWLINE_xXBetween 6 months and <18 years of age (or between 3 years and <18 years of age for rrcHL participants) on day of signing informed consent/assent (the first 3 participants dosed in Part 1 are to be ? 6 years of age)Xx_NEWLINE_xXAge ?18 years oldXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXSubject is ?18 years of age at the time of signing the study informed consent.Xx_NEWLINE_xXAge at least 18 years.Xx_NEWLINE_xXIs of age ? 18 yearsXx_NEWLINE_xX22 years of age and olderXx_NEWLINE_xXPatient is < 75 years of age at time of enrollment.Xx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAre males or females aged ? 18 yearsXx_NEWLINE_xXAge > 18 yearsXx_NEWLINE_xXMen and women at least 18 years of ageXx_NEWLINE_xXAge ? 18.Xx_NEWLINE_xXChildren under the age of 18Xx_NEWLINE_xXParticipants with 1 to less than (<) 18 years of age (Part 1 only), or 1 to 30 years of age, inclusive, if initial diagnosis of mature B-cell non-Hodgkin lymphoma (NHL) occurred at <18 years of age (Part 2 only)Xx_NEWLINE_xX?18 years of age.Xx_NEWLINE_xXPatients must be ? 45 years of ageXx_NEWLINE_xX18 years or olderXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXThe patient is ?18 years old.Xx_NEWLINE_xXThe patient is at least 18 years old.Xx_NEWLINE_xXMust be ? 18 years of age at the time of signing the ICF.Xx_NEWLINE_xXAge: ? 21 years at the time of study entry.Xx_NEWLINE_xXAge between 18 and 70 years (both inclusive).Xx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXAge >= 18 years or age of majority at the participating site, whichever is greaterXx_NEWLINE_xX18 years or olderXx_NEWLINE_xXOlder than 18 years of age at time of consentXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXAge +/> 70Xx_NEWLINE_xX?18 years of age.Xx_NEWLINE_xXSarcoma Patients must be 14 years of age or older. All other patients must be 18 years of age or older.Xx_NEWLINE_xXAge ?18 years and ?80.Xx_NEWLINE_xXPaediatric patients aged 2 years to <18 years at the time of informed consentXx_NEWLINE_xXMen or women, age 18 years or older Part 1:Xx_NEWLINE_xXSubject is > 22 years of age.Xx_NEWLINE_xX? 18 years of age.Xx_NEWLINE_xXPatients must be less than 18 years of age at the time of diagnosis.Xx_NEWLINE_xXMales and females ? 18 years of age.Xx_NEWLINE_xX45 years of age or less.Xx_NEWLINE_xXAge ?18 years. Because no dosing or adverse event data are currently available on the use of ipilimumab or indoximod in patients <18 years of age, children are excluded from this study.Xx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXMales and females 18 years old or older.Xx_NEWLINE_xXCreatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73^2 or serum creatinine based on age/gender as follows:\r\n* Age 1 month to < 6 months: 0.4 for males and 0.4 for females\r\n* Age 6 months to < 1 year: 0.5 for males and 0.5 for females\r\n* Age 1 to < 2 years: 0.6 for males and 0.6 for females\r\n* Age 2 to < 6 years: 0.8 for males and 0.8 for females\r\n* Age 6 to < 10 years: 1 for males and 1 for females\r\n* Age 10 to < 13 years: 1.2 for males and 1.2 for females\r\n* Age 13 to < 16 years: 1.5 for males and 1.4 for females\r\n* Age >= 16 years: 1.7 for males and 1.4 for females\r\n** Participants with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tractXx_NEWLINE_xXAge > 18 yearsXx_NEWLINE_xXDONOR: age >= 12 and =< 75 yearsXx_NEWLINE_xXPatient must be at least 18 years old at the time of consent.Xx_NEWLINE_xXMust be > = 18 years of age.Xx_NEWLINE_xXAge ? 12 months and < 18 yearsXx_NEWLINE_xXDONOR: Donor is at least 18 years of ageXx_NEWLINE_xXAge >/= to 18 yearsXx_NEWLINE_xXMust be at least 18 years of age.Xx_NEWLINE_xXPatients must be at least 18 years old.Xx_NEWLINE_xXAged 18 years or olderXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXBecause no dosing or adverse event data are currently available on the use of enzalutamide and CRLX101 in patients < 18 years of age and prostate cancer is not common in children < 18 years of age, children are excluded from this study.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXAge ?18 years on the day of signing informed consent.Xx_NEWLINE_xXPatients who are ? 18 years of age.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge >18 yearsXx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXMales ?18 years of age at the time of signing consentXx_NEWLINE_xXAge >= 1 year and < 25 years at the time of screening; exception: participants with recurrent, progressive, or refractory medulloblastoma and are >= 1 and < 40 years of age at the time of study screening are eligible for screeningXx_NEWLINE_xXSTRATUM A: Age >= 1 year and < 25 years at the time of screeningXx_NEWLINE_xXSTRATUM B: Age >= 1 year and < 25 years at the time of study enrollmentXx_NEWLINE_xXSTRATUM C: Age >= 10 years and < 40 years at the time of study enrollmentXx_NEWLINE_xXSTRATUM C: Participant must be skeletally mature as defined as females with a bone age > 15 years and males with a bone age > 17 yearsXx_NEWLINE_xXMales or females ?18 years of age.Xx_NEWLINE_xXMen and women of age ?18 years.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXMen and women of age ?18 years.Xx_NEWLINE_xX2 to less than 19 years of age.Xx_NEWLINE_xXMales ? 18 years of age on the day of consenting to the study.Xx_NEWLINE_xXAge ?18 years at the time of informed consent.Xx_NEWLINE_xXIs aged ?20 years old in Japan or ?18 years old in other countriesXx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAge ? 18 years old at the time of signing the informed consentXx_NEWLINE_xXPatient is at least 18 years of age.Xx_NEWLINE_xXAge >=18 years at time of signing Informed Consent FormXx_NEWLINE_xXAge >18 years and ? 70 years at the time of enrollmentXx_NEWLINE_xXSubjects must ?18 years of ageXx_NEWLINE_xXAge 18 or olderXx_NEWLINE_xX18 years and older (Japan-20 years and older)Xx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXParticipant must be >= 18 years of age.Xx_NEWLINE_xX0 to 2 for Participants >= 75 years of age orXx_NEWLINE_xX0 to 3 for Participants >= 18 to 74 years of age.Xx_NEWLINE_xXAge ?12 years oldXx_NEWLINE_xXMales and Females, age ? 18 years oldXx_NEWLINE_xXMales and Females, age ? 18 years oldXx_NEWLINE_xXPatients must be ? 18 years of age.Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXPatient must be > 18 years of age.Xx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXAged at least 2 months and less than 18-years-old on Day 1 ANDXx_NEWLINE_xX? 12 years of ageXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXBe ? 18 years of age on day of signing informed consent.Xx_NEWLINE_xXBe 18 years of age or older and femaleXx_NEWLINE_xXDonor age >= 18 yearsXx_NEWLINE_xXMen over 18 years of age.Xx_NEWLINE_xXAge ?18 years at the time of signing informed consent.Xx_NEWLINE_xXAge >= 18 yearsXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge >21 yearsXx_NEWLINE_xX0 for (age <61 years), +2 for (age 61-70 years), +4 for (age >71 years).Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAt least 18 years old at the time of informed consentXx_NEWLINE_xXBe ? 18 years of age at time of consentXx_NEWLINE_xXAge greater than or equal to 16 years old; if patients 16-17 years old are enrolled in the trial, they will only be enrolled after 3 patients >= 18 years old have been treated, and the treatment has been shown to be safeXx_NEWLINE_xXPatient is at least 18 years of age and <90 years of age at the time Informed Consent is signed.Xx_NEWLINE_xXPatients ?18 years and ?80 years old (The 3 first patients at Dose Level 1 will be < 65 years old. Enrollment of patients ? 65 years old must be approved by the DSMB after the completion of cohort 1).Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXbe ?18 years of age;Xx_NEWLINE_xXPatient is ? 18 years old at the time of informed consent.Xx_NEWLINE_xXPatients must be ? 18 years of age.Xx_NEWLINE_xXThe first 3 subjects enrolled on this study will be 18 years of age or olderXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ?18 years at the time of informed consentXx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXPatients >= 18 years of age with relapsed/refractory Ph-positive ALL.Xx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXSubject is ?18 years of age at the time of signing the study informed consent.Xx_NEWLINE_xXThe pediatric cohort is defined as age younger than 18 years.Xx_NEWLINE_xXAge 18 or more yearsXx_NEWLINE_xXAged ? 18 years.Xx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXMust be 18 years of age or older.Xx_NEWLINE_xXAge ? 18 years at the time of consent.Xx_NEWLINE_xXFemales ?18 years of ageXx_NEWLINE_xXAge ?18 years;Xx_NEWLINE_xXSubjects ? 18 years of age at screeningXx_NEWLINE_xX? 75 years of age ORXx_NEWLINE_xXof 0 to 2 for participants ? 75 years of age orXx_NEWLINE_xXof 0 to 3 for participants between 18 to 74 years of age.Xx_NEWLINE_xXDONOR: At least 18 years of ageXx_NEWLINE_xXBe 18 years of age or older and femaleXx_NEWLINE_xXAge 12 to 65 yearsXx_NEWLINE_xXPatients must be at least 18 years of ageXx_NEWLINE_xXAged at least 18 yearsXx_NEWLINE_xXPatient is at least 18 years of ageXx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXPatients must be at least 18 years of age.Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXMen and women, ? 65 years of age.Xx_NEWLINE_xXSubject is ?18 years of ageXx_NEWLINE_xXAdults 18 years of age or older.Xx_NEWLINE_xXDONOR: Age > 14 yearsXx_NEWLINE_xXDONOR: Ability of donors < 18 years of age to undergo bone marrow harvestXx_NEWLINE_xX?18 years of ageXx_NEWLINE_xXAge greater than or equal to 18 years old at the time of informed consentXx_NEWLINE_xXPatients ?18 years of age at the time of signature of the ICFXx_NEWLINE_xXAge 40 years or older; this age cutoff is justified because breast cancers in women under the age of 40 are known to have a significantly higher risk of IBTR presumably due to underlying biologic differencesXx_NEWLINE_xXAge:\r\n* Phase 1: >= 6 and =< 21 years of age at time of enrollment\r\n* Phase 2: >= 6 and =< 21 years of age at diagnosisXx_NEWLINE_xXMinimum age of 18 yearsXx_NEWLINE_xXAdults ?18 years of ageXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAge > 18 years.Xx_NEWLINE_xXAge ? 18 years old (? 20 years old in Japan);Xx_NEWLINE_xXSubjects at least 18 years of age or older at the time of consent.Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXDONOR: At least 18 years of ageXx_NEWLINE_xXWomen age 21 or older who have:Xx_NEWLINE_xXMales and females >=18 years of age (at the time consent is obtained)Xx_NEWLINE_xXAdults ?18 years of ageXx_NEWLINE_xX18 years of age and olderXx_NEWLINE_xXAge ? 16 yearsXx_NEWLINE_xXPatient age criteria: age >= 18 and =< 45 years (myeloablative regimen 1; age >= 18 and =< 80 years (nonmyeloablative regimen 2) at the discretion of the investigator(s); age >= 18 and =< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy may receive reduced intensity regimen 3Xx_NEWLINE_xX< 70 years of age with no matched 5/6 or 6/6 sibling donor - patients >= 70 and =< 75 years of age may be eligible if they have a co-morbidity score =< 2Xx_NEWLINE_xX> 18 years oldXx_NEWLINE_xXPatients must be ? 18 years old.Xx_NEWLINE_xXAge > 18Xx_NEWLINE_xXAge ?18 years at the screening visit.Xx_NEWLINE_xXAge 18 or more yearsXx_NEWLINE_xXMales and females ? 18 years of ageXx_NEWLINE_xXAge * 18 yearsXx_NEWLINE_xXDONOR: Age >= 18 and =< 70 yearsXx_NEWLINE_xXAged ? 18 years.Xx_NEWLINE_xXDONOR: Age 18 to 70 years of ageXx_NEWLINE_xXAll participants >= 18 years of age must be willing to sign a durable power of attorneyXx_NEWLINE_xXAppropriate written consent – adult or parent/guardian if patient is < 18 years of age and minor information sheet if patient is > 8 years of ageXx_NEWLINE_xXAge >= 40 to < 75 years; patients 18 to 39 years of age will be eligible only if the investigator has determined that the patient has comorbidity(ies) precluding conventional allogeneic transplantation with full intensity myeloablative conditioningXx_NEWLINE_xXBe 18 years of age on day of signing informed consent.Xx_NEWLINE_xXPatient is between 18 and 75 years of age, inclusive.Xx_NEWLINE_xX18 years or olderXx_NEWLINE_xXAt least 18 years old;Xx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXbe over age 18Xx_NEWLINE_xX?18 years of ageXx_NEWLINE_xX18 years of age or older at screening; outside the U.S. and European Union, an older limit could apply depending on local regulation (eg, 19 years and older for South Korea and 20 years and older for Taiwan).Xx_NEWLINE_xXAge (at the time of consent/assent): ?16 years of ageXx_NEWLINE_xX18 years or olderXx_NEWLINE_xXFemale subjects who are at least 18 years of age at the time of informed consentXx_NEWLINE_xXDONOR: Must be 18 years of age or olderXx_NEWLINE_xX18 years and olderXx_NEWLINE_xXPatients must be 18 years of age or older.Xx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXMales and females ? 18 years of ageXx_NEWLINE_xXDONOR: Age =< 60 years of ageXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAdequate renal function as evidenced by: a) Serum creatinine based on age/gender as below. If serum creatinine is greater than maximum serum creatinine for age/gender as shown in the table below, then creatinine clearance (or radioisotope glomerular filtration rate [GFR]) must be greater than 70 milliliter/minute/1.73 square meter (mL/min/1.73 m2). Maximum Serum Creatinine in milligrams/deciliter (mg/dL) for male: i. Age 2 to less than 6 years = 0.8 ii. Age 6 to less than 10 years = 1.0 iii. Age 10 to less than 13 years = 1.2 iv. Age 13 to less than 16 years = 1.5 v. Age greater than or equal to 16 years = 1.7 Maximum Serum Creatinine (mg/dL) for Female: vi. Age 2 to less than 6 years = 0.8 vii. Age 6 to less than 10 years = 1.0 viii. Age 10 to less than 13 years = 1.2 ix. Age 13 to less than 16 years = 1.4 x. Age greater than or equal to 16 years = 1.4 The threshold creatinine values in this Table were derived from the Schwartz formula for estimating glomerular filtration rate using child length and stature data published by the CDC. b) Urine dipstick less than 2+ for proteinuria. Participants who have greater than or equal to 2+ proteinuria on dipstick urinalysis should undergo a spot protein-creatinine (P/C) ratio that should be Grade less than 2. c) No clinical evidence of nephrotic syndrome.Xx_NEWLINE_xX? 18 years of age.Xx_NEWLINE_xXDONOR: Must be 18-80 years of age, inclusiveXx_NEWLINE_xXAge > 18 years at time of study entryXx_NEWLINE_xXAge ? 18 years with the capacity to give written informed consentXx_NEWLINE_xXAge ? 80 yearsXx_NEWLINE_xXAge < 80 years and at least 1 of the following conditions:Xx_NEWLINE_xXPatients must be > than 12 months and ? 21 years of age at the time of study enrollment.Xx_NEWLINE_xXAged ? 18 years, voluntarily consented to the study.Xx_NEWLINE_xXMan or woman >= 18 years old.Xx_NEWLINE_xXChildren (< 18 years of age), pregnant women, University of California employees or students, or prisoners will be excluded from this studyXx_NEWLINE_xXPatients age 18 to 70 years old; eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician; patients age 2-17 years may be enrolled after at least 10 adults (ages 18-70 years old) have been assessed for safety at day 30Xx_NEWLINE_xXAre at least age 18 at screening (Visit 1)Xx_NEWLINE_xXPatient must be > 18 yearsXx_NEWLINE_xXAge < 60 yearsXx_NEWLINE_xXAged ? 18 years.Xx_NEWLINE_xXDONOR: Age >= 18 yearsXx_NEWLINE_xXAge-adjusted serum creatinine < 1.5 x normal for ageXx_NEWLINE_xXAge: ? 21 years at the time of diagnosis.Xx_NEWLINE_xXMales and females at least 18 years of age.Xx_NEWLINE_xXAny patient with both metastatic ependymoma and age < 3 years at the time of enrollmentXx_NEWLINE_xXAge <18-years-old.Xx_NEWLINE_xXPatient is 18 years and older.Xx_NEWLINE_xXAge 12 months to <21 yearsXx_NEWLINE_xXPatients 18 years or older will provide written consent. A parent or legal guardian of a patient <18 years of age will provide informed consent and patients 11 to 18 years of age will provide written assent or as per participating institutional policy.Xx_NEWLINE_xXAge ? 50Xx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAre 18 years of age or older.Xx_NEWLINE_xXPatients must be 18 years of age or older.Xx_NEWLINE_xXMen and women aged 18 years and overXx_NEWLINE_xXPatient is < 18 years of ageXx_NEWLINE_xXFor Phase I Only: Age >/=18 yearsXx_NEWLINE_xXAge: up to and including 18 years at diagnosis of Haemophagocytic LymphohistiocytosisXx_NEWLINE_xXDONOR: At least 18 years of ageXx_NEWLINE_xXDONOR: Age >= 0.5 yearsXx_NEWLINE_xXAge 18 or olderXx_NEWLINE_xXMust be > = 50 years of age.Xx_NEWLINE_xXAge > or = 15 yearsXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXMen and women patients 18 years of age and upXx_NEWLINE_xXDONOR: Less than 18 years oldXx_NEWLINE_xXAge > 18Xx_NEWLINE_xXAge at least 18 years.Xx_NEWLINE_xXMust be 2 - 45 years of age and at least 10 kgXx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXAge between 18 and 75 years, inclusive.Xx_NEWLINE_xXAged 18 years or olderXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXBe between the ages of ?18 and ?65 yearsXx_NEWLINE_xXGroup A : Individuals > 18 years of age with previously untreated AML who are able and should receive up to 2 cycles of induction chemotherapy with 7+3 as determined by the treating physicianXx_NEWLINE_xXAge: \r\n* Stratum I (TMI containing arm): 18-60 years of age\r\n* Stratum II (non TMI arm): 18-70 years of ageXx_NEWLINE_xXDONOR: Age >= 12 yearsXx_NEWLINE_xXDONOR: Age >= 12 years of ageXx_NEWLINE_xXpatients who are age 18 or olderXx_NEWLINE_xXAge 18 years or older, males and females.Xx_NEWLINE_xXAge > 16 years.Xx_NEWLINE_xXAge ?18 years at the time of signing the informed consent form.Xx_NEWLINE_xXAge 70 years or older for AML and 60 years or older for MDSXx_NEWLINE_xXAged =< 3 years at diagnosis (not age of transplant)Xx_NEWLINE_xXIf > 18 years old, prior myeloablative transplant within the last 6 monthsXx_NEWLINE_xXPatients must be >18 years of age.Xx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXParticipants must be > 18 years of ageXx_NEWLINE_xXAge ? 18 years old.Xx_NEWLINE_xXAge: ?12 months to <18 years old at the time of informed consentXx_NEWLINE_xXAge ?18 years;Xx_NEWLINE_xXwithin the last 5 years ORXx_NEWLINE_xXPatients <18 years of ageXx_NEWLINE_xXAge of at least 18 years.Xx_NEWLINE_xXPatients aged 18 years or olderXx_NEWLINE_xXMen and women, ? 18 years of ageXx_NEWLINE_xXCriteria 2 Males or females ? 18 years of ageXx_NEWLINE_xX>18 yearsXx_NEWLINE_xXAge ? 18 years at the time of screening or age of consent according to local lawXx_NEWLINE_xXage <18 years;Xx_NEWLINE_xXBetween 18 and 80 years of age inclusive, at the time of signing the informed consent.Xx_NEWLINE_xXAge ?18 years at the screening visit.Xx_NEWLINE_xXIs 18 Years and older in the United States or 20 Years and older in JapanXx_NEWLINE_xXMales or non-pregnant, non-breastfeeding females 18 years-of-age or olderXx_NEWLINE_xXBe > 18 years of age on day of signing informed consent.Xx_NEWLINE_xXMales or non-pregnant, non-breastfeeding females 18 years-of-age or olderXx_NEWLINE_xXSubject is ? 18 years of age at the time of signing the informed consent form (ICF)Xx_NEWLINE_xXMales and females, age ?18 and ? 65 years of ageXx_NEWLINE_xXMales and females, age ?18 and ? 75 years of ageXx_NEWLINE_xXAge 55 years and 1 year or more of amenorrheaXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXMen and women 18 years of age or olderXx_NEWLINE_xXAge 18-76 yearsXx_NEWLINE_xXAge 18 years or older;Xx_NEWLINE_xXPatients at least eighteen (18) years of age with histologically proven, progressive and/or refractory SM.Xx_NEWLINE_xX18 years of age or older.Xx_NEWLINE_xXPost- menopausal female patients, 18 years of age or greater.Xx_NEWLINE_xXAged between 18 and 75 years, inclusive.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXPatients must be >_18 years of ageXx_NEWLINE_xXPatients must be age >/= 18 years.Xx_NEWLINE_xXMales or females ? 18 years of age at screening.Xx_NEWLINE_xXAge >/= 18 years.Xx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXMales or females at least 18 years of ageXx_NEWLINE_xXMen and women age 18 and olderXx_NEWLINE_xXAge > 18 years. Because no dosing or adverse event data are currently available on the use of AR-67 in patients < 18 years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable.Xx_NEWLINE_xXAge ? 18 years with HCT comorbidity index < 3Xx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXAge >18 yearsXx_NEWLINE_xXMan or woman, age >18 yearsXx_NEWLINE_xXAge > 18 yearsXx_NEWLINE_xXAge ?18 years;Xx_NEWLINE_xXPatients must be 18 years of age.Xx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAge > = 18 years of ageXx_NEWLINE_xXAge < 18 years of ageXx_NEWLINE_xXAge >18 yearsXx_NEWLINE_xX18 years and older.Xx_NEWLINE_xXAge equal to or greater than 18 years and life expectancy > 10 weeks.Xx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAge between 18 and 70 years, inclusive.Xx_NEWLINE_xXFemales at least 18 years of ageXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAge ? 18 years at time of signing informed consent form.Xx_NEWLINE_xXSubjects who are ?18 years of age on the date of written informed consent.Xx_NEWLINE_xXStratum 1 (IDH wild-type): Patients must be >= 3 years of age and =< 21 years of age at the time of enrollmentXx_NEWLINE_xXStratum 2 (IDH mutant): Patients must be >= 3 years of age and =< 25 years of age at the time of enrollmentXx_NEWLINE_xX102 Age ? 18 at the time of informed consent.Xx_NEWLINE_xXMinimum age 18 years (in Japan, minimum age 20 years).Xx_NEWLINE_xXAge ?18 years at the time of consent.Xx_NEWLINE_xXPatients must be at least 18 years of age.Xx_NEWLINE_xX2. Age >= 18 years at time of informed consent. Both men and women and members of all races and ethnic groups will be included.Xx_NEWLINE_xXAge >/= 12 yearsXx_NEWLINE_xXWomen and men at least 18 years of age or older.Xx_NEWLINE_xXAge ? 2 years.Xx_NEWLINE_xXMales or females aged ?18 years at screening.Xx_NEWLINE_xXMales and females ? 18 years of ageXx_NEWLINE_xXAge greater than 18 years.Xx_NEWLINE_xXAge ? 18 years oldXx_NEWLINE_xXAge ? 18 years and ? 60 yearsXx_NEWLINE_xXAge ? 18 years and ? 75 yearsXx_NEWLINE_xXAge >18 years;Xx_NEWLINE_xXHigh dose TBI regimen: 18 to =< 45 yearsXx_NEWLINE_xXPatients 18 to =< 45 years: Karnofsky (>= 18 years old) >= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1Xx_NEWLINE_xXBe ? 18 years of age.Xx_NEWLINE_xXMales >=18 years of age (at the time written consent is obtained for screening)Xx_NEWLINE_xXAge ?60 orXx_NEWLINE_xXAdults, age 60 years or older at the time of diagnosisXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXThe subject must be >= 12 years of age at the time of consentXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ? 18 years old.Xx_NEWLINE_xXAge >/= 60 yearsXx_NEWLINE_xXAge (must have body surface area [BSA] >= 0.55 m^2):\r\n* Phase I: >= 3 and =< 21 years of age\r\n* Phase II: >= 3 and =< 35 years of ageXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXAge > 18 yearsXx_NEWLINE_xX>= 55 years of age with AML of any risk classification, or 18-54 years of age with intermediate or high risk AML as defined by National Comprehensive Cancer Network (NCCN) risk assignmentXx_NEWLINE_xXDONOR: Age >= 18 to =< 77 years oldXx_NEWLINE_xXDONOR: Age >= 13 years old (yo) and =< 75 yearsXx_NEWLINE_xXDONOR: Age less than 18 yearsXx_NEWLINE_xXParticipants must be ? 18 years of age.Xx_NEWLINE_xXSubjects of either sex, of all races and ethnic groups, and ?18 years of ageXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xX-  Males and females at least 18 years of ageXx_NEWLINE_xXMinimum Age 18 years (in certain territories, the minimum age requirement may be\n             higher eg age 20 years in Japan and Taiwan)Xx_NEWLINE_xXDONOR: 14-75 years of ageXx_NEWLINE_xXAge:\r\n* Part A1: Patients must be >= 12 months and < 18 years of age at the time of study enrollment\r\n* Part A2: Patients must be > 6 months and < 12 months of age at the time of study enrollment; patients will enroll one dose level behind the dose level at which patients in Part A1 are enrollingXx_NEWLINE_xXAge:\r\n* Phase 1 (Part A)\r\n** Patients must be > than 12 months and =< 21 years of age at the time of study enrollment\r\n* Phase 2 (Part B and Part C)\r\n** Patients must be > than 12 months and =< 30 years of age at the time of study enrollmentXx_NEWLINE_xXFor patients < 18 years of age, their legal guardian must give informed consent; pediatric patients will be included in age-appropriate discussion in order to obtain verbal assentXx_NEWLINE_xXDurable power of attorney form offered (patients >= 18 years of age only)Xx_NEWLINE_xXPatients must be > 18 years old.Xx_NEWLINE_xX-  Males and females ? 18 years of ageXx_NEWLINE_xXAbility to give informed consent; for patients < 18 years of age their legal guardian must give informed consent; pediatric patients will be included in age-appropriate discussion in order to obtain verbal assent\r\n* Durable power of attorney form completed (patients >= 18 years of age only)\r\n* Female patients (and when relevant their male partners) must be willing to practice birth control (including abstinence) during and for two months after treatment, if of childbearing potentialXx_NEWLINE_xXDONOR: For donors >= 18 years of age, ability to give informed consentXx_NEWLINE_xXCreatinine below age-adjusted maximum limits in the table below OR creatinine clearance >= 60 mL/min/1.73 m^2 assessed within seven (7) days prior to the start of therapy\r\n* 0.8 mg/dl (patients =< 5 years of age)\r\n* 1.0 mg/dl (patients 5 < age =< 10 years of age)\r\n* 1.2 mg/dl (patients 10 < age =< 15 years of age)\r\n* 1.5 mg/dl (patients > 15 years of age)Xx_NEWLINE_xXAssignment of DPA to a family member or guardian should be offered to all patients 18 years of age or olderXx_NEWLINE_xXFemale subjects age >= 18 years (males with breast cancer are eligible)Xx_NEWLINE_xXDONOR: Age >= 0.5 yearsXx_NEWLINE_xXAged 18 years or older at the time of consentXx_NEWLINE_xXAge (at the time of consent/assent): ?6 months to ?21 yearsXx_NEWLINE_xXCohort 4 only: ?10 years to ?21 yearsXx_NEWLINE_xXAge 18 - 80 years; age > 80 allowed at investigator discretion if performance status ? 1; and each organ system score ? 2 using cumulative illness rating scale (CIRS)Xx_NEWLINE_xXAge ? 18 years or the minimum legal adult age (whichever is greater) at the time of Informed consent.Xx_NEWLINE_xXAdult aged 18 years or olderXx_NEWLINE_xXMen and women ? 18 years of ageXx_NEWLINE_xX18 years of age at the time of signing informed consentXx_NEWLINE_xXSubjects must be ?18 years of age.Xx_NEWLINE_xXSubject must be ?18 years of age.Xx_NEWLINE_xXMen and Women ? 18 years of ageXx_NEWLINE_xX18 years and olderXx_NEWLINE_xXAge < 18 years and > 1 month (< 1 month upon approval by Sponsor)Xx_NEWLINE_xXPatients must be > 24 months and < 30 years of age when registered on study.Xx_NEWLINE_xXPatients must be > 2 years and < 30 years of age when registered on study.Xx_NEWLINE_xXWomen and men ?18 years of age with performance status of 0 or 1Xx_NEWLINE_xXPatient must be ?18 years of ageXx_NEWLINE_xXMen and women ?18 years of age.Xx_NEWLINE_xXAge 18 years or older.Xx_NEWLINE_xXMust be at least 18 years of ageXx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xXMen and women: ? 65 years of age OR > 18 and < 65 years of age, provided that they meet at least one of the following criteria:Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXSubjects must be 18 years or older (? 15 years for PMBL)Xx_NEWLINE_xXMen and women 18 years of age or older.Xx_NEWLINE_xX18 years and olderXx_NEWLINE_xXThe patient is ? 18 years old.Xx_NEWLINE_xXThe patient is ? 18 years old.Xx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXMen and women 18 to 85 years of age, inclusive.Xx_NEWLINE_xXPatients aged ?18 years at time of screeningXx_NEWLINE_xXAge ? 13 years.Xx_NEWLINE_xXAge at diagnosis at least 18 years.Xx_NEWLINE_xXAge ? 18 years oldXx_NEWLINE_xXSubject is age 18 years or older;Xx_NEWLINE_xXSubject is ? 18 years of age at the time of signing the informed consent form (ICF)Xx_NEWLINE_xXAge ? 55 years and one year or more of amenorrheaXx_NEWLINE_xXRenal function defined as: A serum creatinine based on age/gender as follows: Maximum Serum Creatinine (mg/dL). Age Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1.0 1.0 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 ? 16 years 1.7 1.4.Xx_NEWLINE_xXAge 3 at the time of screening to age 21 at the time of initial diagnosisXx_NEWLINE_xXSubjects age ? 18 years with relapsed or refractory AML after ? 2 prior induction regimens, at least one containing anthracyclinesXx_NEWLINE_xXSubjects ? 60 years of age with newly diagnosed AMLXx_NEWLINE_xXBe ?18 years of age;Xx_NEWLINE_xX? 18 years of age.Xx_NEWLINE_xXAdult patients age 18 years or older.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge greater than or equal to (>=)18 yearsXx_NEWLINE_xX18 years of age or older.Xx_NEWLINE_xX18 years or olderXx_NEWLINE_xXWomen ? 18 and ? 75 years of age.Xx_NEWLINE_xXMales or females aged 18 years or olderXx_NEWLINE_xXThe patient must be ?18 years of ageXx_NEWLINE_xXAge 18 years and olderXx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xXFemale patient, age 18 years or older;Xx_NEWLINE_xXPatients must be ?18 years of ageXx_NEWLINE_xXAge >= 70 yearsXx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXFemales, 18 years of age or olderXx_NEWLINE_xXPatients must be ? 18 years of ageXx_NEWLINE_xXWomen (?18 years of age) with metastatic breast cancer not amenable to curative treatment by surgery or radiotherapy.Xx_NEWLINE_xXAge 18 years and aboveXx_NEWLINE_xX< 55 years of ageXx_NEWLINE_xX12 years and older unless not permitted by local regulations; in that case 18 years old and olderXx_NEWLINE_xXAge ? 18 at time of informed consentXx_NEWLINE_xXAge (at the time of consent) ?18 years of ageXx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xX18 years and older.Xx_NEWLINE_xX?45 years of age and has not had menses for over 2 yearsXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xX18 years or olderXx_NEWLINE_xXSubject is ?18 years of ageXx_NEWLINE_xXAge ?18 years at the time of screeningXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXPatients ?18 years of age;Xx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXAge >18 yearsXx_NEWLINE_xXAt least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects < 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is ? 18 years of ageXx_NEWLINE_xXMen and women 18 years of age to 80 years of age of any ethnic origin or race at the time of signing the ICD.Xx_NEWLINE_xXMen and women 18 years old or older (or local age of majority)Xx_NEWLINE_xXMales and females at least 18 years of age at the time of signing of the informed consent document.Xx_NEWLINE_xXAge >21 yearsXx_NEWLINE_xX? 18 years of age.Xx_NEWLINE_xXAge ? 18 years of age at the time of signing the informed consent document.Xx_NEWLINE_xXPatients must be ? 18 years of age.Xx_NEWLINE_xXPatients must be males ? 18 years of ageXx_NEWLINE_xXSubjects must be ?18 years of age at the time of signing the Informed Consent Form (ICF);Xx_NEWLINE_xXAdults (aged ? 18 years)Xx_NEWLINE_xXAge ? 18 with prior bilateral oophorectomyXx_NEWLINE_xXAge ? 60 yearsXx_NEWLINE_xXAge of 18 years or olderXx_NEWLINE_xXPatients must be ? 18 years of age.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAge superior or equal to 18 years or country's legal age of majority if the legal age is superior to 18 years old.Xx_NEWLINE_xXAge ? 60 yearsXx_NEWLINE_xXMales and females aged >=18 years (for Japan only: Age >=20 years at time of signing Informed Consent Form) with histologically confirmed metastatic colorectal cancer (mCRC).Xx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge greater than or equal to 18 years at the time of informed consent.Xx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAgeXx_NEWLINE_xXPatients must be ? 12 months of age and ? 30 years of age at the time of study entry for patients diagnosed with DIPG.Xx_NEWLINE_xXPatients must be ? 12 months of age and ? 21 years of age at the time of study entry for patients diagnosed with HGG.Xx_NEWLINE_xXMen ? 18 years of age at the time of informed consent.Xx_NEWLINE_xXAge ? 50;Xx_NEWLINE_xXMen & women ?20 years of ageXx_NEWLINE_xXAge > = 18 yearsXx_NEWLINE_xXAge ?18Xx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXAdult women (? 18 years of age) with advanced TNBC.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXFemale, age ? 18 yearsXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAre at least 18 years of age at the time of informed consentXx_NEWLINE_xXMen and women ? 18 years of ageXx_NEWLINE_xX18 years or olderXx_NEWLINE_xXBe 18 years of age or older on day of signing informed consent.Xx_NEWLINE_xXMen and women ? 18 years of ageXx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAll patients must be at least 18 years of ageXx_NEWLINE_xXAge >= 18 yearsXx_NEWLINE_xXPostmenopausal females, 18 years of age or older.Xx_NEWLINE_xXIs 18 years of age or olderXx_NEWLINE_xXAged 18 years or older, with lymphoid malignancies of B-cell origin including:Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAge ?18 years at the time of signing the informed consent document.Xx_NEWLINE_xXA serum creatinine =< upper limit of normal (ULN) based on age/gender as follows:\r\n* Age 1 month to < 6 months: 0.4 for males, 0.4 for females\r\n* Age 6 months to < 1 year: 0.5 for males, 0.5 for females\r\n* Age 1 to < 2 years: 0.6 for males, 0.6 for females\r\n* Age 2 to < 6 years: 0.8 for males, 0.8 for females\r\n* Age 6 to < 10 years: 1 for males, 1 for females\r\n* Age 10 to < 13 years: 1.2 for males, 1.2 for females\r\n* Age 13 to < 16 years: 1.5 for males, 1.4 for females\r\n* Age >= 16 years: 1.7 for males, 1.4 for femalesXx_NEWLINE_xXMales or females aged at least 18 years (or any age greater than 18 years as determined by country legislation) at the time of informed consentXx_NEWLINE_xXPatients must be >/= 18 years of age.Xx_NEWLINE_xXSubject is < 18 years of age.Xx_NEWLINE_xXPatient of age between 50 to 75 years, inclusive.Xx_NEWLINE_xXAge > 18 years at the time of consent.Xx_NEWLINE_xXAdult Women (? 18 years old).Xx_NEWLINE_xXParticipant is female and ? 18 years of age or older if required by local laws or regulationsXx_NEWLINE_xXAge greater than or equal to 18 years.Xx_NEWLINE_xXAge ? 18 years oldXx_NEWLINE_xX?18 years old.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXMale or female, greater than or equal to (>=) 18 years of age (or having reached the age of majority according to local laws and regulations, if the age of majority is > 18 years of age); [i.e. >= 20 years of age in Japan])Xx_NEWLINE_xXAge ? 15 years and < 71 years at the time of signing the informed consent formXx_NEWLINE_xXSubjects ? 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for subjects < 18 years of age. Pediatric subjects will be included in age appropriate discussion in order to obtain assent.Xx_NEWLINE_xXSubject is ? 75 years of age.Xx_NEWLINE_xX12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)Xx_NEWLINE_xXBe at least 55 years of ageXx_NEWLINE_xXPatients must be ? 18 years of age.Xx_NEWLINE_xXMen and women ? 18 years of age, at the time of signing the informed consent form (ICF).Xx_NEWLINE_xXMan or woman greater than or equal to (>=) 18 years of ageXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXPatient must be ? 18 years old.Xx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXBe 22 years of age or olderXx_NEWLINE_xXSubject is 21 years of age or older.Xx_NEWLINE_xXMales and females 18 years old and greaterXx_NEWLINE_xXPatient is at least 18 years of age at randomization.Xx_NEWLINE_xXParticipant is ? 18 years of age at the time of signing the informed consent form.Xx_NEWLINE_xXPatient ? 18 years of age. Patient life expectancy > 6 months. Eastern cooperative group (ECOG) of 0 or 1Xx_NEWLINE_xXWomen ? 18 years of age.Xx_NEWLINE_xXSubject is ? 18 years of age or is considered an adult according to local regulation at the time of signing informed consent.Xx_NEWLINE_xXAge ?18 years (? 20 years in Japan).Xx_NEWLINE_xXAge: at least 20 years of ageXx_NEWLINE_xXPatients must be at least 18 years old.Xx_NEWLINE_xXCohort 1 patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\r\n* Note: patients in Cohort 1 will be stratified as follows:\r\n** Stratum 1: Patients >= 11 years of age but < 18 years\r\n** Stratum 2: Patients >= 11 years of age but < 50 yearsXx_NEWLINE_xXAged at least 18 years. Japan patients aged at least 20 years.Xx_NEWLINE_xXMen and women ? 18 years of ageXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXMen and women ? 18 years of ageXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXAge >/= 18 yearsXx_NEWLINE_xXPatients must be 18 years or older at time of consent.Xx_NEWLINE_xXBe ? 18 years of age on day of signing informed consent.Xx_NEWLINE_xXSubject is female ? 18 years of age (at the time of signing the informed consent form) with metastatic breast cancer not amenable to curative treatment by surgery or radiotherapy.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXMen and women ? 18 years of ageXx_NEWLINE_xXAged at least 18 yearsXx_NEWLINE_xXAge ? 18 years at the time of consentXx_NEWLINE_xXAdults ? 18 years of age.Xx_NEWLINE_xXAge ?18 years;Xx_NEWLINE_xXPatients must be ? 18 years of age.Xx_NEWLINE_xXAge 18 or older at time of study entryXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXMen or women participants 18 years or older.Xx_NEWLINE_xXMen and women ?18 years old.Xx_NEWLINE_xXMen and women ? 18 years of ageXx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAged at least 18 years.Xx_NEWLINE_xXAge at least 18 years.Xx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAged at least 18 years.Xx_NEWLINE_xXSubject must be ?18 years of age.Xx_NEWLINE_xXMales or non-pregnant, non-breastfeeding females 18 years-of-age or older.Xx_NEWLINE_xXAge greater than18 yearsXx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXMen and women, ages ? 18 years of ageXx_NEWLINE_xX18 years or olderXx_NEWLINE_xXAge <18-years-old.Xx_NEWLINE_xXAdult participants greater than or equal to 18 years of ageXx_NEWLINE_xX?18 years of age.Xx_NEWLINE_xXAge ? 18 years of ageXx_NEWLINE_xXMales and females ? 18 years oldXx_NEWLINE_xX? 18 years at time of consent.Xx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXAge ?60Xx_NEWLINE_xXPatient must be at least 18 years old.Xx_NEWLINE_xXAge 21 years or younger at the time of initial ALL diagnosis and age > 1 year at the time of study treatment initiation.Xx_NEWLINE_xXAge ? 18 years (Age ? 12 years for patients with bone sarcomas).Xx_NEWLINE_xXAge ? 18 years at the time of consent.Xx_NEWLINE_xXAge: >=18 years of age at the time of providing informed consent.Xx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXMinimum age in Japan is 20 years.Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xX2 years to 21 years of ageXx_NEWLINE_xXSubject must be greater than or equal to 18 years of age.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXSubjects must be>/= 18 years of age at the time of informed consent, because no dosing or adverse event data are currently available on the use of eltrombopag in children.Xx_NEWLINE_xXMales or females aged at least 18 years (or any age greater than 18 years as determined by country legislation) at the time of informed consent (Screen 1).Xx_NEWLINE_xXPatients must be ? 18 years of age.Xx_NEWLINE_xXUp to 65 years of ageXx_NEWLINE_xXthe patient is 65 years of age or olderXx_NEWLINE_xXAge >= 18 yearsXx_NEWLINE_xXAge <18-years-old.Xx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAged at least 18 years. Patients from Japan aged at least 20 years.Xx_NEWLINE_xXAge > 18 yearsXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xX? 18 years of age.Xx_NEWLINE_xXAge < 18-years-old.Xx_NEWLINE_xXAdult patient, >/= 18 years of ageXx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXMen or women ?18 years of ageXx_NEWLINE_xXMales and female subjects ? 18 years of age at the time of enrollment, except in Japan where subjects must be ? 20 years of age at the time of enrollmentXx_NEWLINE_xXAge >= 65years.Xx_NEWLINE_xXMen & women ? 18 years of ageXx_NEWLINE_xXPatients aged > 18Xx_NEWLINE_xXMales and females aged ?18 years;Xx_NEWLINE_xXDONOR: Age >= 18 years and =< 60 yearsXx_NEWLINE_xXAged ? 18 years.Xx_NEWLINE_xXPatients 18 years old or greaterXx_NEWLINE_xXAge 60-75 years at the time of diagnosis of AMLXx_NEWLINE_xXAge 18 or older.Xx_NEWLINE_xXBe at least 18 years of ageXx_NEWLINE_xXMen & women ?18 years of ageXx_NEWLINE_xXMen & women ?18 years of ageXx_NEWLINE_xXPatients 18 or olderXx_NEWLINE_xXAge > 21 yearsXx_NEWLINE_xXMales and females age ?18 yearsXx_NEWLINE_xXSubjects age ?18 yearsXx_NEWLINE_xXPatients > or = 18 years oldXx_NEWLINE_xXAge >/= 60 yearsXx_NEWLINE_xXDONOR: 18 to 75 years of ageXx_NEWLINE_xXDONOR: At least 18 years of ageXx_NEWLINE_xXBe older than or be 18 years of ageXx_NEWLINE_xX? 18 years old at the time of informed consent.Xx_NEWLINE_xX>= 18 years of ageXx_NEWLINE_xXAge of >/= 18 years.Xx_NEWLINE_xX?18 years of ageXx_NEWLINE_xXPatients ?18 years of age.Xx_NEWLINE_xXAge ? 18 years of ageXx_NEWLINE_xXDONOR: Donors must be 18-75 years of age, inclusiveXx_NEWLINE_xXAge > 60 yearsXx_NEWLINE_xX6 months to less than 18 years of age at the time of consent.Xx_NEWLINE_xXAge at least 18 years at enrollment.Xx_NEWLINE_xXPatients aged 20 years and older at the time of tentative registration (with no upper age limit)Xx_NEWLINE_xXFemales 18 to 80 years of ageXx_NEWLINE_xXSubjects younger than 18 years of ageXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge > = 18 years at the time of signing the informed consent form.Xx_NEWLINE_xXAge >= 18 years.Xx_NEWLINE_xXAge greater than or equal to 18 years, either sex.Xx_NEWLINE_xXMen and women aged ?18 yearsXx_NEWLINE_xXFemale gender and age ? 18 years at time of study entryXx_NEWLINE_xXPatients must be >/= 18 years old.Xx_NEWLINE_xXMales and females ? 18 years of ageXx_NEWLINE_xX?18 years oldXx_NEWLINE_xXPatients must be ? 15 years of age.Xx_NEWLINE_xXDONOR: 14-75 years of ageXx_NEWLINE_xXAge >=18 years at the time of consent.Xx_NEWLINE_xXAge ?18Xx_NEWLINE_xXAt University of Oklahoma: age > 17 years old and =< 55 years for recipientXx_NEWLINE_xX18F FLT CANDIDATE TRANSPLANT RECIPIENT: Age >= 18 years old at National Cancer Institute (NCI), and age > 4 years and < 24 years at Children’s National Medical CenterXx_NEWLINE_xXAt least 18 years of age;Xx_NEWLINE_xXE 05. Less than 18 years (or country's legal age of majority if the legal age is >18 years).Xx_NEWLINE_xXEighteen years of age or aboveXx_NEWLINE_xXAge >=18 years oldXx_NEWLINE_xX?18 years oldXx_NEWLINE_xXAge > than 18 years at the time of signing the informed consent form.Xx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAge eighteen years or older on the day of consent.Xx_NEWLINE_xXWomen (regardless of menopausal status) or men ?18 years of age (or per local regulations).Xx_NEWLINE_xXUnable to receive intensive chemotherapy regimens at enrollment, based on one of the following: I. Age ? 75 years, or II. Age < 75 years with at least 1 of the following co-morbidities:Xx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXAge ? 12 yearsXx_NEWLINE_xXPatients must be 18 years of age or older.Xx_NEWLINE_xXBe ? 18 years of age at time of consentXx_NEWLINE_xXSubjects 70 years of age or older; OR subjects 60-69 years of age who have one or more comorbidities.Xx_NEWLINE_xXAge ?18 years. A patient may be of either sex and of any race/ethnicity.Xx_NEWLINE_xXAge > 18 yearsXx_NEWLINE_xXMales and females ? 18 years of age;Xx_NEWLINE_xXPatients under the age of 18.Xx_NEWLINE_xX18 years or olderXx_NEWLINE_xXFor ESFT patients age ?12 years.Xx_NEWLINE_xXFor ESFT patients age ?12 years.Xx_NEWLINE_xXAge ?18 years (non-ESFT candidates)Xx_NEWLINE_xXAge >=18 yearsXx_NEWLINE_xXAge 18 and olderXx_NEWLINE_xXMen or women at least 18 years of age or older at time of study entryXx_NEWLINE_xXMales or females ? 18 years of ageXx_NEWLINE_xXAge ? 65 yearsXx_NEWLINE_xXPediatric patients (younger than 18 years) will be excluded.Xx_NEWLINE_xXage ?40 years through ?85 years of age;Xx_NEWLINE_xXage 18yrs or olderXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXPatients must be 3 years of age or olderXx_NEWLINE_xXFemales, aged 18 years or olderXx_NEWLINE_xXAge < 3 years at time of diagnosis for all histological diagnosisXx_NEWLINE_xXPatients must be 18 years old or older.Xx_NEWLINE_xXAge < 30 yearsXx_NEWLINE_xXDONOR: Age 18 years or olderXx_NEWLINE_xXAge >/= 18 yearsXx_NEWLINE_xXAge greater than or equal to 18 yearsXx_NEWLINE_xXAge >= 16 years (age > 18 years to participate in optional symptom burden assessment)Xx_NEWLINE_xXDONOR: Age < 12 yearsXx_NEWLINE_xXDONOR: Age less than 12 yearsXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXPatients aged 18 years or older, inclusiveXx_NEWLINE_xXBe 18 years of age or older.Xx_NEWLINE_xXAge ?18 years of age.Xx_NEWLINE_xXAge 18 years.Xx_NEWLINE_xXWomen ? 18 years of ageXx_NEWLINE_xXMales and females ?18 years of ageXx_NEWLINE_xXSubjects must be males or females age 18 years or older.Xx_NEWLINE_xXAge ? 18 years at the time of consent.Xx_NEWLINE_xXAge ? 18 years at the time of consentXx_NEWLINE_xXDonor >= 18 years oldXx_NEWLINE_xX?18 years of ageXx_NEWLINE_xXMales and females age ? 18 yrs;Xx_NEWLINE_xXSubject is 18 years of age or more at the time of signing the Informed Consent FormXx_NEWLINE_xX18 years of age.Xx_NEWLINE_xXMinimum age 18 years (in certain territories, the minimum age requirement may be higher (e.g. 20 years in Japan and Taiwan)Xx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xXMales and females >=18 years of age (at the time consent is obtained).Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXFemale subjects with age ? 18 yearsXx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXDONOR: Age < 60 yearsXx_NEWLINE_xXDONOR: Age: less than age 18 or older than age 60Xx_NEWLINE_xXMales and females ?18 years of age for NSCLC, TNBC, and CRPCXx_NEWLINE_xXMales and females ?16 years of age for NMCXx_NEWLINE_xXMales 18 years of age and aboveXx_NEWLINE_xXAge ? 18 years old.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXMales or non-pregnant, non-breastfeeding females 18 years-of-age or older.Xx_NEWLINE_xXMen and women ? 18 years of age.Xx_NEWLINE_xX>18 years of age.Xx_NEWLINE_xXFemale participants of non-childbearing potential, ?18 years of ageXx_NEWLINE_xXPatients must be >18 years of ageXx_NEWLINE_xXMen and women, aged 18 years or olderXx_NEWLINE_xXAge <18-years-old.Xx_NEWLINE_xXAll subjects must be >/= 18 years at the first screening examination / visitXx_NEWLINE_xXAge >/= 18 years.Xx_NEWLINE_xXAge ? 18 years old.Xx_NEWLINE_xX? 6 months and < 25 years of ageXx_NEWLINE_xXPatients > 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for patients < 18 years of age. Pediatric patients will be included in age appropriate discussion in order to obtain assentXx_NEWLINE_xXAge >/= 18 yearsXx_NEWLINE_xXEligible study subjects in Part 1 and Part 2 must be 18 years or olderXx_NEWLINE_xX?18 years of ageXx_NEWLINE_xXMales and females ? 18 years of age at the time of signing the informed consent document (ICD).Xx_NEWLINE_xXSubjects at least 18 years of ageXx_NEWLINE_xXAge < 55 years old and > 4 monthsXx_NEWLINE_xXMales and females ?18 years of age at the time of signing the consent form.Xx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXAdults >/= 18 years oldXx_NEWLINE_xXAge >=18 years (For subjects in Taiwan, Age >= 20 years)Xx_NEWLINE_xX60 years of age or older, orXx_NEWLINE_xX18 years of age or older and decline methotrexate-based treatment.Xx_NEWLINE_xXDONOR: age >= 18 years oldXx_NEWLINE_xXMust be ?18 years of ageXx_NEWLINE_xXMales and females >=18 years of age (at the time consent is obtained).Xx_NEWLINE_xXDONOR: Age > 18 years (yr)Xx_NEWLINE_xX18 years or older, of either sex, and of any raceXx_NEWLINE_xXSubject is 22 years of age or olderXx_NEWLINE_xXMSC DONOR: age >= 18 years, =< 30 yearsXx_NEWLINE_xXPatients over 18 years of age, regardless of race of genderXx_NEWLINE_xXDurable power of attorney form offered (patients >= 18 years of age only)Xx_NEWLINE_xX? 18 years of age.Xx_NEWLINE_xX7. Age ?18 years.Xx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAged ? 18 yearsXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAge > or = to 16 yearsXx_NEWLINE_xX22 years of age or olderXx_NEWLINE_xXCaregiver: Age >= 18 yearsXx_NEWLINE_xXMales or females, age 18 years or older.Xx_NEWLINE_xXAge of 18 years or olderXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge >= 18 years.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge 8-16 years old at the time of consentXx_NEWLINE_xXSubjects ? 18 years of age who have signed informed consentXx_NEWLINE_xXIs >18 years old;Xx_NEWLINE_xXBe ? 18 years of age on day of signing informed consent.Xx_NEWLINE_xXAge ?21 yearsXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge 19 years or older (age of consent in Nebraska); age 18 years or older (applicable to states where the age of majority is 18)Xx_NEWLINE_xXAdult subjects; age ? 18Xx_NEWLINE_xXMen and women of age 18 or olderXx_NEWLINE_xXSubjects ? 18 years age and ? 80 years of age at the time of signing the informed consent form.Xx_NEWLINE_xXAge 18 or olderXx_NEWLINE_xXPatient should be 15 years of age or olderXx_NEWLINE_xXPatients younger than 15 years of ageXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXPatients must be 18 years or older.Xx_NEWLINE_xXAdults (aged ? 18 years)Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge ? 18 years;Xx_NEWLINE_xXPatient is at least 18 years of age.Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXPatients ? 18 years of age.Xx_NEWLINE_xXAge > or = to 21 yearsXx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXAge 18 to 70 years of age.Xx_NEWLINE_xXAge 18 and olderXx_NEWLINE_xXMales and females ?18 years of age (at the time consent is obtained);Xx_NEWLINE_xX?18 years of age.Xx_NEWLINE_xXAge 18 years and older.Xx_NEWLINE_xXINCLUSION CRITERIA - HPC-A CELL DONOR: At least 18 years of ageXx_NEWLINE_xXAged 18 years and olderXx_NEWLINE_xX18 years and olderXx_NEWLINE_xXMales and postmenopausal females, 18 years or olderXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXDONOR: At least 18 years of ageXx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXAge >/= 18 yearsXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xX? 18 years oldXx_NEWLINE_xXMen or women > 18 years oldXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXMen and women ? 18 years of ageXx_NEWLINE_xXGlomerular filtration rate >= 60 cc/min/1.73 m^2, or serum creatinine based on age as follows:\r\n* Age 1 to 2 years: 0.6 for males and 0.6 for females\r\n* Age 2 to 6 years: 0.8 for males and 0.8 for females\r\n* Age 6 to 10 years: 1 for males and 1 for females\r\n* Age 10 to < 13 years: 1.2 for males and 1.2 for females\r\n* Age 13 to 16 years: 1.5 for males and 1.4 for females\r\n* Age > 16 years: 1.7 for males and 1.4 for femalesXx_NEWLINE_xXAdult patients, >/= 18 years of ageXx_NEWLINE_xX18 years of age or older, female, any raceXx_NEWLINE_xXAge between 18 and 75 years old (both inclusive)Xx_NEWLINE_xX12 < 18 years of ageXx_NEWLINE_xXPatient must be ? 18 years of age.Xx_NEWLINE_xXAge eighteen years or olderXx_NEWLINE_xXAdult patients, >/= 18 years of ageXx_NEWLINE_xXPatients must be ? 21 years of age at the time of enrollment.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXAge>18Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXFemale, ?18 years of ageXx_NEWLINE_xXNon-pregnant female adults at least 18 years of age at time of informed consentXx_NEWLINE_xXAge >= 18 yearsXx_NEWLINE_xXMales and females ? 18 years of age.Xx_NEWLINE_xXMales or females of any race at least 18 years of ageXx_NEWLINE_xXAge >21 yearsXx_NEWLINE_xXMales age ? 18 yearsXx_NEWLINE_xXAt least 18 years of age.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAge ? 18 years. .Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXSkeletally mature adult males and females 18 years of age or older.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ?21 yearsXx_NEWLINE_xXAge ? 18 years of age at the time of signing the Informed Consent Form.Xx_NEWLINE_xXMales or females at least 18 years of ageXx_NEWLINE_xXSubject must be ?18 years of ageXx_NEWLINE_xXBe at least 18 years of age at the time of consentXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXDONOR: At least 18 years of ageXx_NEWLINE_xXBe at least 18 years of ageXx_NEWLINE_xXAge ? 18 to ? 80 years at the time of signing the informed consent formXx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAged 18 years or olderXx_NEWLINE_xXAge 18 years and older.Xx_NEWLINE_xXPatient is 18 years of age or olderXx_NEWLINE_xXAge >= 18 yearsXx_NEWLINE_xXAge: >3 months to <18 years of age.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXMen and women 18 and olderXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xX18 years of age or older.Xx_NEWLINE_xXMan or woman >= 18 years old.Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXSubjects >=18 years old.Xx_NEWLINE_xXThe age limit - 18 or older. Gender is not a criterion.Xx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXAdults >/= 18 years oldXx_NEWLINE_xX? 18 years old Part 2, dose expansion:Xx_NEWLINE_xXAt least 18 years of age at time of study entryXx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXAge ? 18 years of age, at the time of informed consent.Xx_NEWLINE_xXMales and females ? 18 years of ageXx_NEWLINE_xXIs the subject between 18 years old and 80 years old inclusive?Xx_NEWLINE_xXAge <18 years.Xx_NEWLINE_xXMen and women ?18 years of ageXx_NEWLINE_xXAge >18 years of age.Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXMales and females >=18 years of age (at the time consent is obtained).Xx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge >21 yearsXx_NEWLINE_xX? 18 years of age.Xx_NEWLINE_xXAge between 18 and 75 yearsXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXThe subject is at least 18 years old.Xx_NEWLINE_xXPatient is an adult ? 18 years old at the time of informed consent.Xx_NEWLINE_xXMales or non-pregnant, non-breastfeeding females 18 years-of-age or older.Xx_NEWLINE_xXAge >=18 yearsXx_NEWLINE_xXAdult patient, >/= 18 years of ageXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge >=18 yearsXx_NEWLINE_xXSubject must be at least 18 years of age.Xx_NEWLINE_xXAge 18 years or aboveXx_NEWLINE_xXPatients must be men and women >= 18 years of age.Xx_NEWLINE_xXEighteen (18) years of age or olderXx_NEWLINE_xXAdult participants, >/= 18 years of ageXx_NEWLINE_xXAdult patients, >/= 18 years of ageXx_NEWLINE_xXMales and non-pregnant, non-lactating females, 18 years of age or olderXx_NEWLINE_xX?18 years.Xx_NEWLINE_xXMales and females ? 18 years of ageXx_NEWLINE_xXParticipants must be ?18 years since no dosing or adverse event data are currently available on the use of OGX-427 in participants <18 years of age.Xx_NEWLINE_xXMales and females >= 18 years of ageXx_NEWLINE_xXWomen ? 18 years of ageXx_NEWLINE_xXMales and females 18 years of age and older at the time of screeningXx_NEWLINE_xXAge >/=18 years old.Xx_NEWLINE_xXAge 4 through 65 yearsXx_NEWLINE_xXMen and women ? 18 years of ageXx_NEWLINE_xX18-39 years oldXx_NEWLINE_xXEighteen years of age or aboveXx_NEWLINE_xXMen or women > 18 years oldXx_NEWLINE_xXMen or women 18 years of age or olderXx_NEWLINE_xX-  Age >18 years.Xx_NEWLINE_xXIs 0 months (at least 37 weeks gestation) to <18 years of ageXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXMales and females ? 18 years of ageXx_NEWLINE_xXAge ?12 yearsXx_NEWLINE_xXAge <18 years.Xx_NEWLINE_xXPatients must be < 30 years of age when registered on study.Xx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXThe patient is ?18 years old.Xx_NEWLINE_xXMales >=18 years of age (at the time consent is obtained)Xx_NEWLINE_xXAll subjects must be ? 18 years at the first screening examination / visitXx_NEWLINE_xXMale or female between one month and <18 years of age (inclusive) at the time of signing the informed consent form (Part C and Part D between 12 months and <18 years of age, inclusive).Xx_NEWLINE_xXFor the initial dose escalation to identify the maximum tolerable or PK target dose, age between 2 years and <18 years (inclusive) at the time of signing the informed consent form. Children < 2 years of age will be enrolled once the age specific expansion cohorts are open.Xx_NEWLINE_xXPHASE I: >= 3 years and =< 18 years of age at the time of study enrollment, if able to swallow whole capsulesXx_NEWLINE_xXAged at least 18 years.Xx_NEWLINE_xXBe ?18 years of age.Xx_NEWLINE_xXMales and females greater than or equal to 18 years of ageXx_NEWLINE_xXAdults > 18 years of ageXx_NEWLINE_xX?18 years oldXx_NEWLINE_xXDONOR: At least 18 years of ageXx_NEWLINE_xXPatients 18 years or olderXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAdult patients, >/= 18 years of ageXx_NEWLINE_xXMales and females ? 18 years of age.Xx_NEWLINE_xXMen, 18 years of age or older;Xx_NEWLINE_xXAged 18 years or olderXx_NEWLINE_xXAge greater than or equal to 18 years.Xx_NEWLINE_xXPatients must be > 18 years of ageXx_NEWLINE_xXAge of </= 18 years.Xx_NEWLINE_xXAge ? 18 years of ageXx_NEWLINE_xXPatient is ? 18 years of age on the day of consent signatureXx_NEWLINE_xXMen or women ?18 years oldXx_NEWLINE_xXAdult participants, greater than or equal to (>/=) 18 years of ageXx_NEWLINE_xXAge greater than or equal to (>=) 18 years, including males and females;Xx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXDonor must be 18 to 70 years of age inclusive.Xx_NEWLINE_xXRecipient must be 18 to 75 years of age inclusive.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xX18 years of ageXx_NEWLINE_xXAge > or = to 18 years.Xx_NEWLINE_xXPatient is ?18 years of age.Xx_NEWLINE_xXMust be ? 18 years of ageXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge ?18 yearsXx_NEWLINE_xXAge 18 years or older.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXMust be at least 18 years of ageXx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXMen or women ? 18 years oldXx_NEWLINE_xXPatients must be 18 years of age or olderXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXSubjects must be 18 years of age or olderXx_NEWLINE_xXat least 18 years of ageXx_NEWLINE_xXMust be at least 18 years of ageXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXThe patient is >= 18 years of age at the time of signature of the first informed consent form.Xx_NEWLINE_xXAge initiated after limitation - 18 years or older. A separate pediatric study is proposed to evaluate tolerance to the drug in children.Xx_NEWLINE_xXAge > 18 years at the time of consent.Xx_NEWLINE_xXPatients must be female at least 18 years of age.Xx_NEWLINE_xXAdults >/=18 yearsXx_NEWLINE_xXMales ? 18 years of ageXx_NEWLINE_xXAge >/= 18 years.Xx_NEWLINE_xXDONOR: Age 18 years to 80 yearsXx_NEWLINE_xXPatient's age is 18 years or older, both genders.Xx_NEWLINE_xXFemales at least 18 years old;Xx_NEWLINE_xXThe participant is age ? 18 yearsXx_NEWLINE_xX18 years or olderXx_NEWLINE_xXPatient is ? 15 and < 75 years of age.Xx_NEWLINE_xXThe patient is >= 18 years of age at the time of signature of the informed consent form.Xx_NEWLINE_xXAge 18 years or older.Xx_NEWLINE_xXAge ? 18 years at the time of signing consentXx_NEWLINE_xX1 to < 18 years of ageXx_NEWLINE_xXAdults ? 18 years oldXx_NEWLINE_xXBe older than 21 years of age.Xx_NEWLINE_xXPatients must be greater than 18 years of ageXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ? 18 to ? 80 years at the time of signing the informed consent formXx_NEWLINE_xXAge 18 years or older and willing and able to provide informed consent;Xx_NEWLINE_xXThe parent must be at least 18 years of age to ensure the age of majority across all participating sites to legally consent their childXx_NEWLINE_xXAge 18 years and olderXx_NEWLINE_xXMen and women age 18 and olderXx_NEWLINE_xXIC from the subject or assent from the subject and consent from a parent or guardian, if the subject is < 18 years of ageXx_NEWLINE_xXAge 18 years or moreXx_NEWLINE_xXAge ? 18 years at the time of screening.Xx_NEWLINE_xXFemale patients 18 years of age or older;Xx_NEWLINE_xXSubject is ?18 years of age at the time of signing the study informed consent.Xx_NEWLINE_xXMales or females age ?18 years at the time of informed consent form (ICF)Xx_NEWLINE_xXMen and women 18 years old or olderXx_NEWLINE_xXBe over 18 years of ageXx_NEWLINE_xXMales and females of 18 to 89 years of age.Xx_NEWLINE_xXAge 18 years of age or older at last transplantXx_NEWLINE_xXThe child is 3-8 years of age at time of enrollmentXx_NEWLINE_xXOne parent (? 18 years of age) can be present for all sessionsXx_NEWLINE_xXPROVIDER ELIGIBILITY: The participant is greater than 18 years of ageXx_NEWLINE_xXEXCLUSION FOR PARENTS: Parent is < 18 years of ageXx_NEWLINE_xXEXCLUSION FOR PARENTS: Patient is < 2 years of age, or > 24 years of ageXx_NEWLINE_xXEXCLUSION CRITERIA FOR PATIENTS: Patient is < 2 years of age, or > 24 years of ageXx_NEWLINE_xXPHASE 2: PATIENT ELIGIBILITY: Age 18-25Xx_NEWLINE_xXPHASE 3B: PATIENT ELIGIBILITY: Age 18-25Xx_NEWLINE_xXCo-survivors must be over the age of 18 yearsXx_NEWLINE_xXQualitative interviews will be conducted in patients (age 10 years or older) with their assent/consent; patients (age 10-17.9 years) will be asked to complete surveys that have been validated in this age group and that offer insight into the usefulness of the BMT Roadmap; patients (18 years or older) will be asked to complete surveysXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXPATIENTS: Age 30-89 yearsXx_NEWLINE_xXAge\r\n* For centers that will use fluconazole as the antifungal comparator:\r\n** Age >= 3 months and < 21 years\r\n* For centers that will use voriconazole as the antifungal comparator:\r\n** Age >= 2 years and < 21 yearsXx_NEWLINE_xXWomen age 18 years or older who self-identifies as African-AmericanXx_NEWLINE_xXFor donors < 18 years of age, their legal guardian must give informed consent, the donor must give written assentXx_NEWLINE_xXFor donors >= 18 years of age, ability to give informed consentXx_NEWLINE_xXCancer diagnosis prior to 22 years of age, irrespective of current ageXx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXAge >= 18 yearsXx_NEWLINE_xXFemale, Age ?18 years.Xx_NEWLINE_xXDONOR: Age >= 18 to =< 75 years oldXx_NEWLINE_xXPatient refusal to participate (any age), or parental refusal to participate for patients less than 18 years of ageXx_NEWLINE_xXBe at least 18 years of ageXx_NEWLINE_xXAre between 55 and 85 years of ageXx_NEWLINE_xXAge > 18 years at the time of consent.Xx_NEWLINE_xXMales age ? 18 yearsXx_NEWLINE_xXIs ?18 years or the minimum legal adult age (whichever is greater) and ?75 years (at Screening);Xx_NEWLINE_xXFor dose-escalation stage (tablets): age at study entry >= 6 years to < 18 yearsXx_NEWLINE_xXFor dose-escalation stage (suspension): age at study entry >= 6 months to < 18 years. Participants <1 year of age will not be enrolled until >= 6 participants >= 1 year to < 18 years of age have received at least one cycle of therapy with suspension and until safety and pharmacokinetic assessment of these participants have been conducted.Xx_NEWLINE_xXPatients age ?60 years who:Xx_NEWLINE_xXAny patient age ? 70 years.Xx_NEWLINE_xXPatients age ?60 years who:Xx_NEWLINE_xXAny patient age ? 75 years.Xx_NEWLINE_xXAge 18 years or olderXx_NEWLINE_xXCaregivers: At least 18 years of ageXx_NEWLINE_xXPatient and caregiver: Children under the age of 18 do not receive HSCTs in either programXx_NEWLINE_xXAge 18 or olderXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXSubjects must be at least 18 years of ageXx_NEWLINE_xXOver age 18Xx_NEWLINE_xX18 years of age or older at screening.Xx_NEWLINE_xXAge 5-17 years at time of study enrollmentXx_NEWLINE_xXMales or females aged ?18 years on day of consent.Xx_NEWLINE_xX65 years of age or olderXx_NEWLINE_xXSubject is ?18 years of age.Xx_NEWLINE_xXAge 21 or older;Xx_NEWLINE_xXUnder age 21;Xx_NEWLINE_xX< 18 years of ageXx_NEWLINE_xX21 years of age or olderXx_NEWLINE_xXMales or females aged 18 years or olderXx_NEWLINE_xXBe 18 years of age or older and give written informed consent.Xx_NEWLINE_xXDONOR: Age >= 18 yearsXx_NEWLINE_xXDONOR: Age < 18 yearsXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXCAREGIVERS ONLY: Must be an adult (>=18 years old)Xx_NEWLINE_xXMust be >= 18, but < 70 years of age with no matched 5/6 or 6/6 sibling donor - patients >= 70 and =< 75 years of age may be eligible if they have a Co-Morbidity score =< 2Xx_NEWLINE_xXAge 30 or olderXx_NEWLINE_xXAge 40 years old to 74 years oldXx_NEWLINE_xX1) 18 years of age and olderXx_NEWLINE_xXEducational component: men over the age of 18Xx_NEWLINE_xXPatient must have had a cancer diagnosis < 22 years of age, irrespective of current ageXx_NEWLINE_xXMales and females,age 1 year(365 days) to < 18 (17 years and 364 days) years.Xx_NEWLINE_xXAge ? 18 (or legal age of majority for sites outside US).Xx_NEWLINE_xX18 years or olderXx_NEWLINE_xXPatients must be between 18 and 60 years of ageXx_NEWLINE_xXAge >= 18 yearsXx_NEWLINE_xXRECIPIENT: Age 18 to 75 yearsXx_NEWLINE_xXAge >= 18 years and =< 70 yearsXx_NEWLINE_xXAge >= 18 yearsXx_NEWLINE_xXAre at least 18 years oldXx_NEWLINE_xXHave at least one child under age 18 who is living in the same householdXx_NEWLINE_xXA second parent/caregiver will be eligible to participate in the study if they are at least 18 years old and have at least on child under age 18 who is living in the same household and participating in the studyXx_NEWLINE_xXAge >= 18 years for the feasibility phase; age >= 10 years old AND >= 50 kg for the phase II portionXx_NEWLINE_xXPatient is at least 18 years of ageXx_NEWLINE_xXDONOR: Age >= 18 yearsXx_NEWLINE_xXDONOR: Age < 18 yearsXx_NEWLINE_xXAge ?18 and ?65 yearsXx_NEWLINE_xXAge > 75 yearsXx_NEWLINE_xXAdult (?18 years)Xx_NEWLINE_xXMust be >= 18, but < 70 years of age with no matched 7/8 or 8/8 sibling donor - patients >= 70 and =< 75 years of age may be eligible if they have a co-morbidity score =< 2Xx_NEWLINE_xX2. Males or females aged ?18 years;Xx_NEWLINE_xXFemale age 18 to 55 yearsXx_NEWLINE_xXAge: 0-21 years at the time of diagnosis.Xx_NEWLINE_xXAge >= 18 years, with histologically confirmed diagnosis of Barrett's Esophagus without dysplasiaXx_NEWLINE_xXAge: 0-21 years at the time of diagnosis.Xx_NEWLINE_xXAre 50 years of age or olderXx_NEWLINE_xXAim 5: 18 years or olderXx_NEWLINE_xXWomen (?18 years of age) with metastatic breast cancer not amenable to curative treatment by surgery or radiotherapy.Xx_NEWLINE_xXAdult (?18 years old)Xx_NEWLINE_xXAdult (aged ? 18 years)Xx_NEWLINE_xXAbility to give informed consent for patients greater than 18 years of age. For patients less than 18 years of age the legal guardian must give informed consent.Xx_NEWLINE_xX? 18 years of ageXx_NEWLINE_xXAge: 0-21 years at the time of diagnosis.Xx_NEWLINE_xXSubject is ? 18 years of age at the time of signing the informed consent form (ICF).Xx_NEWLINE_xX?18 years of age at the time of signing informed consentXx_NEWLINE_xX50 to 75 years of ageXx_NEWLINE_xXLHW: age 18 or olderXx_NEWLINE_xX18-35 years oldXx_NEWLINE_xXAt least 18 years of ageXx_NEWLINE_xXBetween 4.0 years and < 11.0 years of age at the time of recruitmentXx_NEWLINE_xXAge 18-75 years (patient is older than 18.0 and less than 76.0 years old)Xx_NEWLINE_xXAge ? 55 years and one year or more of amenorrheaXx_NEWLINE_xXAdult patients at least 18 years of ageXx_NEWLINE_xXInclusion Criteria:\n\n          -  referrals from the New York State Smokers' Quitline\n\n          -  at least 18 years of ageXx_NEWLINE_xX18-40 years old,Xx_NEWLINE_xXIndividuals greater than or equal to 18 years of ageXx_NEWLINE_xXIndividuals who are less than 18 years of ageXx_NEWLINE_xXSigned written informed consent (by parent if patient is < 18 years of age, or by patient, if he or she is >= 18 years of age)Xx_NEWLINE_xXPatient assent for those >= 10 years of age and < 18 years of age for whom a parent provides informed consentXx_NEWLINE_xXPatients age ?18 years oldXx_NEWLINE_xXMust be 21 years of age or older.Xx_NEWLINE_xX>18 years old.Xx_NEWLINE_xXAge 21-75 years at screeningXx_NEWLINE_xXCHILD: Has a caregiver, >= 18 years of age that is willing to participate in the studyXx_NEWLINE_xXAge less than 18 years.Xx_NEWLINE_xXAged 18 to 65 years inclusiveXx_NEWLINE_xX18 years of age or older at the time of consent;Xx_NEWLINE_xXAge < 18 yearsXx_NEWLINE_xXPatient is < 18 years old at the time of the drug administrationXx_NEWLINE_xXFor 7T scanning, patients must be 18 years or olderXx_NEWLINE_xXAny patient under age 18 may only participate in 3T imagingXx_NEWLINE_xXPatients under the age of 18 may not participate in 7T imagingXx_NEWLINE_xXCreatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows: NOTE: for MRI imaging serum creatinine measurement must meet the same criteria and be measured within 1 week of the imaging session\r\n* Age 1 month to < 6 months: 0.4 for males; 0.4 for females\r\n* Age 6 months to < 1 year: 0.5 for males; 0.5 for females\r\n* Age 1 to < 2 years: 0.6 for males; 0.6 for females\r\n* Age 2 to < 6 years: 0.8 for males; 0.8 for females\r\n* Age 6 to < 10 years: 1.0 for males; 1.0 for females\r\n* Age 10 to < 13 years: 1.2 for males; 1.2 for females\r\n* Age 13 to < 16 years: 1.5 for males; 1.4 for females\r\n* Age >= 16 years: 1.7 for males; 1.4 for femalesXx_NEWLINE_xXSubjects must be age 18 years or older.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xX?18 years oldXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ?18 years.Xx_NEWLINE_xXAge at treatment 1 to 35 years.Xx_NEWLINE_xXMale or females with an age ? 18 years (? 20 years in Japan)Xx_NEWLINE_xXM/F at least 18 years oldXx_NEWLINE_xXIs at least 18 years of age at the time of consentXx_NEWLINE_xX18 years of age or olderXx_NEWLINE_xXPatients over the age of 18.Xx_NEWLINE_xXAge > 18 yearsXx_NEWLINE_xXNORMAL VOLUNTEERS: Be >= 18 years of ageXx_NEWLINE_xXSubjects aged 18 years or more at the time of consent.Xx_NEWLINE_xXAge is 18 years or older.Xx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXPediatric patients of any age are eligible, including those that may require sedation for MRI; more specifically, children 0-17 years of age and adults >= 18 years of age are eligibleXx_NEWLINE_xX18 years of age or over.Xx_NEWLINE_xXParticipants must be at least 18 years of ageXx_NEWLINE_xXMen and women >18 yearsXx_NEWLINE_xXOlder than 18 years of ageXx_NEWLINE_xXAged at least 18Xx_NEWLINE_xXgreater than or equal to 18 years of ageXx_NEWLINE_xXPatients who are at least 18 years of ageXx_NEWLINE_xXAge >/= 18 yearsXx_NEWLINE_xXUnder 50 or over 74 years of ageXx_NEWLINE_xXAdult patients over 18 years of age;Xx_NEWLINE_xXBe age ? 18 years old.Xx_NEWLINE_xXBe ? 18 years of ageXx_NEWLINE_xXFemale, age of 18 years or older.Xx_NEWLINE_xXPatients younger than 18 yearsXx_NEWLINE_xXAge ? 18 years.Xx_NEWLINE_xXAge: >1 month and <30 years at time of enrollmentXx_NEWLINE_xXAge of 18 years or older at time of entry into the studyXx_NEWLINE_xXAge greater than or equal to 18 years, andXx_NEWLINE_xXage 18+Xx_NEWLINE_xXThe patient is at least 18 years old.Xx_NEWLINE_xXage ? 18 yearsXx_NEWLINE_xXPatients are men or women at least 18 years of age.Xx_NEWLINE_xXFemale, age of 18 years or older.Xx_NEWLINE_xX?18 yearsXx_NEWLINE_xXAge > 65 yearsXx_NEWLINE_xXFemale patients 18 years of age and olderXx_NEWLINE_xXage >=18Xx_NEWLINE_xXWomen who are 18 years or older.Xx_NEWLINE_xXAge ? 18 years at time of consent (19 years if required by local or state laws)Xx_NEWLINE_xXAge of 18 years or older.Xx_NEWLINE_xXAge 18 or olderXx_NEWLINE_xXMales and females of age ? 18 years or of age ? 22 years for those assigned to Optune™ at the time of signing of the informed consent document.Xx_NEWLINE_xXWomen ? 18 years oldXx_NEWLINE_xXMen and women ? 18 years of age, at the time of signing the ICD (Informed Consent Document).Xx_NEWLINE_xXAge ? 18Xx_NEWLINE_xXPatients must be >18 years-of-age.Xx_NEWLINE_xX?18 years of ageXx_NEWLINE_xXMales or females age ?18 years at the time of informed consent.Xx_NEWLINE_xXAge of 16 years or olderXx_NEWLINE_xXPatient is at least 18 years of age.Xx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xXAge ? 18 yearsXx_NEWLINE_xX